Preliminary findings from ongoing Phase I trial of second-generation DMT asset SPL028 indicate the potential for a unique therapeutic profile • Proof-of-concept data from Company’s native DMT program, SPL026, offers potential for an expedited route to an international, multi-site Phase II study with SPL028 in 2024 • Implementation of ongoing operational efficiencies including a reduction in…
